NASDAQ · Medical - Devices

IART (IART) Stock

$19.76 +1.15% NASDAQ: IART Healthcare

Valuation

MetricValue
Price$19.76
Market Cap$1.54B
P/E Ratio5.27
P/B Ratio1.03
P/S Ratio0.65
EPS (TTM)$-6.73
52-Week High$19.98
52-Week Low$8.70
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-38.63%
ROA2.54%
ROCE-47.28%
Gross Margin53.21%
Operating Margin7.53%
Net Margin-30.15%
Debt/Equity1.96
Current Ratio2.54

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.5B$1.6B$1.5B$1.6B$1.6B
Operating Profit$197.0M$239.0M$112.0M$28.0M$68.0M
Net Profit$169.0M$181.0M$68.0M$-7.0M$-516.0M
EPS$1.98$2.16$0.84$-0.09$-6.73
Op Margin12.8%15.3%7.2%1.8%4.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$3.8B$3.9B$3.8B$4.0B$3.6B
Total Liabilities$2.1B$2.1B$2.2B$2.5B$2.6B
Cash$513.0M$457.0M$276.0M$246.0M$235.0M
Borrowings$1.7B$1.6B$1.7B$2.0B$2.0B

Latest News

Is This the Right Time to Hold MYGN Stock in Your Portfolio? Zacks · Jul 15, 2026 Why Integra LifeSciences (IART) Stock Is Up Today StockStory · Jul 9, 2026 Illumina Stock Gains 43.7% in 2026: What's Powering the Rally? Zacks · Jul 9, 2026 Integra (IART) Is Attractively Priced Despite Fast-paced Momentum Zacks · Jul 9, 2026 BMO Capital Initiates Integra LifeSciences at Market Perform With $19 Price Target MT Newswires · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$312.0M$264.0M$140.0M$129.0M$50.0M
Investing Cash Flow$-210.0M$-106.0M$-161.0M$-495.0M$-189.0M
Financing Cash Flow$2.0M$-150.0M$-284.0M$-62.0M$-19.0M
Net Cash Flow$43.0M$-57.0M$-180.0M$-30.0M$-11.0M
Free Cash Flow$264.0M$217.0M$73.0M$25.0M$-31.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.67
EV / EBITDA9.23
FCF Yield-0.94%
Quick Ratio1.95
Interest Coverage0.79
Return 1Y45.00%
Return 3Y-59.38%
Return 5Y-72.36%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCAX $27.81 +2.92% -7.37 $1.52B 0.00%
BFLY $8.28 -1.72% -60.65 $2.20B 0.00%
EYPT $12.41 +1.80% -4.34 $1.04B 0.00%
FTRE $18.43 +4.18% -1.26 $1.75B 0.00%
INMD $15.38 +1.38% 9.72 $884.05M 0.00%

About IART

IART is led by CEO Mojdeh Poul, employs 4,396 people, headquartered in US, publicly traded since 1995.

IART stock trades at $19.76 with a market capitalization of $1.54B. The stock is valued at a price-to-earnings (P/E) ratio of 5.27, price-to-book of 1.03, price-to-sales of 0.65. Over the past 52 weeks the stock has ranged between $8.70 and $19.98, and currently trades 1.1% below its 52-week high.

On profitability, IART generates a return on equity (ROE) of -38.63%, return on capital employed of -47.28%, an operating margin of 7.53%, a net profit margin of -30.15%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides